Insmed reported $1.23B in Assets for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
Acelrx Pharmaceuticals ACRX:US $ 79.59M 7.76M
Alexion Pharmaceuticals ALXN:US $ 18650.2M 547.2M
Alimera Sciences ALIM:US $ 62.1M 16.52M
Arena Pharmaceuticals ARNA:US $ 1084.66M 99.28M
Biomarin Pharmaceutical BMRN:US $ 5898.5M 93.44M
Cytokinetics CYTK:US $ 564.3M 12.76M
Dynavax Technologies DVAX:US $ 647.91M 157.79M
Flexion Therapeutics FLXN:US $ 210.05M 20.33M
Gilead Sciences GILD:US $ 67984M 492M
Heron Therapeutics HRTX:US $ 404.25M 93.32M
Insmed INSM:US $ 1.23B 537.39M
Mirati Therapeutics MRTX:US $ 1355.7M 25.14M
Novartis NVS:US $ 124015M 2263M
Regeneron Pharmaceuticals REGN:US $ 21485.9M 3713.7M
Sarepta Therapeutics SRPT:US $ 2759.07M 6.16M
Seattle Genetics SGEN:US $ 3952.16M 9.17M
Ultragenyx Pharmaceutical RARE:US $ 1512.44M 85.32M
Vertex Pharmaceuticals VRTX:US $ 12221.69M 106.63M